Efficacy and safety of rivaroxaban, colchicine, and famotidine–loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial

SWEETMAN, JENNY orcid.org/0000-0003-1969-4586 and Consortium, STIMULATE-ICP (2026) Efficacy and safety of rivaroxaban, colchicine, and famotidine–loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial. Lancet Infectious Diseases. ISSN: 1474-4457

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© 2026 The Author(s)
Dates:
  • Published (online): 8 July 2026
Institution: The University of York
Academic Units: The University of York > Faculty of Sciences (York) > Health Sciences (York)
Date Deposited: 09 Jul 2026 14:00
Last Modified: 09 Jul 2026 14:00
Published Version: https://doi.org/10.1016/S1473-3099(26)00242-2
Status: Published online
Refereed: Yes
Identification Number: 10.1016/S1473-3099(26)00242-2
Open Archives Initiative ID (OAI ID):

Download

Published Version

Filename: 1-s2.0-S1473309926002422-main.pdf

Description: Efficacy and safety of rivaroxaban, colchicine, and famotidine–loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial

Licence: CC-BY 2.5

CLICK TO DOWNLOAD [thumbnail of Efficacy and safety of rivaroxaban, colchicine, and famotidine–loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial]

Export

Statistics

View Altmetric information about this item.


CORE (COnnecting REpositories)